BETRF Stock Chart & Stats
$0.15
$0.02(15.25%)
At close: 4:00 PM EDT
$0.15
$0.02(15.25%)
Day’s Range― - ―
52-Week Range$0.03 - $0.33
Previous CloseN/A
Volume124.13K
Average Volume (3M)43.71K
Market Cap
$43.23M
Enterprise Value$13.92
Total Cash (Recent Filing)$28.58K
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding161,887,020
10 Day Avg. Volume49,808
30 Day Avg. Volume43,712
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)$2.15B
Bulls Say, Bears Say
Bulls Say
Narrowing LossesThe substantial reduction in annual losses indicates progress toward tighter cost control and a more manageable operating structure. Although profitability remains negative, continued improvement could extend the company’s funding runway and support future development efforts.
Improving Cash-Burn TrendLower operating cash burn reduces the amount of external capital required to sustain research activities. This improvement is strategically helpful for a clinical-stage company, though ongoing negative cash flow means funding dependence has not yet been eliminated.
Reduced Absolute DebtDebt reduction lowers fixed financial obligations and may provide some relief as the company funds its pipeline. The benefit is limited by the small asset base and negative equity, but lower debt still reduces one source of balance-sheet pressure.
Bears Say
No Operating RevenueThe absence of operating revenue means BetterLife Pharma has not yet demonstrated commercial demand or a self-funding business model. Progress therefore depends on financing, partnerships, licensing, or eventual product approvals, all of which remain uncertain.
Persistently Negative EquityDeeply negative equity leaves the company with little balance-sheet cushion to absorb additional losses or development setbacks. It can constrain financing flexibility, increase reliance on new capital, and raise longer-term solvency risk while operations remain unprofitable.
Ongoing External Funding DependencePersistent cash outflows show that the company cannot currently fund operations from internally generated cash. Continued reliance on external financing exposes the pipeline to dilution, funding interruptions, and reduced strategic flexibility if capital becomes unavailable.
BetterLife Pharma News
BETRF FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was $0.03 and its highest was $0.33 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is $43.23M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Sep 30, 2026 which is in 33 days.
How were BetterLife Pharma’s earnings last quarter?
Currently, no data Available
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 161,887,020 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in BETRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BetterLife Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.11%
Trailing 12-Months
Company Description
BetterLife Pharma
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―
Ownership Overview
28.81% Insiders
<0.01% Other Institutional Investors
71.19% Public Companies and
Individual Investors